This systematic review evaluates the safety and efficacy of 5-aminosalicylic acid (5-ASA) for treating ulcerative colitis (UC), finding it effective in both inducing and maintaining remission in UC patients. The study showed remission rates of 50-60% depending on the dosage, with minimal side effects such as headaches and gastrointestinal disturbances.
